Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
RESEARCH TOOLSreports
Vertex Pharmaceuticals (VRTX) Stock Price & Analysis
4,483 Followers
VRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$276.57 - $367.00
Previous Close$349.53
Volume698.15K
Average Volume (3M)1.01M
Market Cap
$90.21B
Enterprise ValueN/A
Total Cash (Recent Filing)$11.24B
Total Debt (Recent Filing)$767.60M
Price to Earnings (P/E)27.0
Beta0.51
Next Earnings
Nov 01, 2023EPS Estimate
$3.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.94
Shares Outstanding258,094,815
10 Day Avg. Volume895,741
30 Day Avg. Volume1,012,297
Standard Deviation0.08
R-Squared0.12
Alpha0.00928
Financial Highlights & Ratios
Price to Book (P/B)6.55
Price to Sales (P/S)36.18
Price to Cash Flow (P/CF)19.90
P/FCF Ratio20.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$382.74Price Target Upside9.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Vertex Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $276.57 and its highest was $367.00 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Nov 01, 2023 which is in 36 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Aug 01, 2023. The company reported $3.89 earnings per share for the quarter, beating the consensus estimate of $3.859 by $0.031.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $3.93.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,094,820 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $3.89 in its last earnings report, beating expectations of $3.859. Following the earnings report the stock price went up 3.066%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Bridgewater Associates, LP. It holds Vertex Pharmaceuticals’s shares valued at 62M.
---
Vertex Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$382.74 (9.15% Upside)
$382.74 (9.15% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 92.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.06%
12-Months-Change
Fundamentals
Return on Equity
24.56%
Trailing 12-Months
Asset Growth
30.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
Top 5 ETFs holding VRTX
Global X S&P 500 Covered Call ETF
$7.16M
iShares ESG Screened S&P 500 ETF
$488.64K
Global X S&P 500 Covered Call & Growth ETF
$151.99K
Global X S&P 500 ESG Covered Call ETF
$8.15K
Global X S&P 500 Tail Risk ETF
$6.02K
Up to five ETFs with an Outperform Smart Score that hold VRTX. The ETFs are listed according to market value of VRTX within the ETF
---